Aeglea BioTherapeutics to Participate in Multiple Conferences in September 2021

Rhea-AI Summary

Aeglea BioTherapeutics, a clinical-stage biotechnology company, will participate in various medical and investor conferences in September 2021. Key events include the Wells Fargo Virtual Healthcare Conference on September 9, the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, and the Cantor Virtual Global Healthcare Conference on September 27. Aeglea will present findings on pegzilarginase for Arginase 1 Deficiency at the MDS Virtual Congress (September 17-22) and the CNS Annual Meeting (September 29 - October 2), highlighting gait kinematics and spasticity analysis.

AUSTIN, Texas, Sept. 1, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced its participation in the following medical and investor conferences: 

Investor Meetings

• 2021 Wells Fargo Virtual Healthcare Conference, September 9
• H.C. Wainwright 23^rd Annual Global Investment Conference, September 13
• 2021 Cantor Virtual Global Healthcare Conference, September 27

Medical Conferences

• International Parkinson and Movement Disorder Society annual congress (MDS Virtual Congress 2021), September 17 - 22
• 50^th Child Neurology Society (CNS) Annual Meeting, September 29 - October 2

At both the MDS Virtual Congress and the CNS Annual Meeting, a poster presentation will outline a subset analysis from the Company's previously reported Phase 1/2 and Phase 2 open label extension studies of pegzilarginase in patients with Arginase 1 Deficiency (ARG1-D). In the poster, analysis of gait kinematics and spasticity was completed using video compilations.

To access live and/or archived Investor Conference webcasts, visit the Events & Presentations section of the Company's website. A replay of Company webcasts is archived on the website for 30 days following presentations.

About Aeglea BioTherapeutics

Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designations. The Company began dosing patients in a Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria in June 2021. AGLE-177 has also been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families. For more information, please visit http://aeglea.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-to-participate-in-multiple-conferences-in-september-2021-301366671.html

SOURCE Aeglea BioTherapeutics, Inc.

FAQ

What conferences will Aeglea BioTherapeutics participate in September 2021?

Aeglea BioTherapeutics will participate in the Wells Fargo Virtual Healthcare Conference on September 9, H.C. Wainwright 23rd Annual Global Investment Conference on September 13, and Cantor Virtual Global Healthcare Conference on September 27.

What presentations will Aeglea BioTherapeutics make at medical conferences?

Aeglea will present a poster outlining analysis from its Phase 1/2 and Phase 2 studies of pegzilarginase for Arginase 1 Deficiency at the MDS Virtual Congress (September 17-22) and the CNS Annual Meeting (September 29 - October 2).

What is pegzilarginase used for?

Pegzilarginase is being developed for the treatment of Arginase 1 Deficiency, a rare metabolic disease.

What is the significance of AGLE-177?

AGLE-177, currently in a Phase 1/2 clinical trial, is being developed for treating Homocystinuria and has received Rare Pediatric Disease Designation.

Where can I find Aeglea BioTherapeutics conference webcasts?

Live and archived webcasts of Aeglea's Investor Conferences can be accessed on the Events & Presentations section of their website.